Takeda Pharmaceutical Files 6-K Report

Ticker: TAK · Form: 6-K · Filed: Mar 30, 2026 · CIK: 0001395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TAK)
Form Type6-K
Filed DateMar 30, 2026
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: foreign-issuer, regulatory-filing, presentation

TL;DR

Takeda dropped a 6-K filing on 3/30/26 with presentations and releases. Check it for deets.

AI Summary

Takeda Pharmaceutical Co Ltd filed a 6-K report on March 30, 2026. The filing includes various documents, such as the 6-K form itself and supplementary exhibits like press releases (EX-99.1) and presentations (EX-99.2), along with numerous graphic files. The content of these exhibits is not detailed in the provided filing information.

Why It Matters

This filing provides an update from Takeda Pharmaceutical Co Ltd to investors and the public, potentially containing important business or financial information.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that typically provides updates and does not inherently signal significant new risks.

Key Players & Entities

  • Takeda Pharmaceutical Co Ltd (company) — Filer of the 6-K report
  • 0001395064 (company) — SEC Filer Identification Number
  • 2026-03-30 (date) — Filing Date and Period of Report

FAQ

What is the primary purpose of a 6-K filing?

A 6-K filing is a report of foreign issuer required by SEC rules 13a-16 and 15d-16, used to provide information that the issuer makes public in its home country or distributes to its security holders.

When was this specific 6-K filing accepted by the SEC?

This 6-K filing was accepted by the SEC on March 30, 2026, at 06:27:15.

What types of documents are included in this filing?

This filing includes the 6-K form itself, an exhibit labeled EX-99.1 (release), an exhibit labeled EX-99.2 (presentation), and numerous graphic files.

What is the SEC accession number for this filing?

The SEC accession number for this filing is 0001395064-26-000104.

What period does this 6-K report cover?

The period of report for this 6-K filing is March 30, 2026.

Filing Stats: 217 words · 1 min read · ~1 pages · Grade level 15.3 · Accepted 2026-03-30 06:27:15

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date March 30, 2026 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.